SATURDAY OCTOBER 17, 2015

12.00-19.00. Registration

AUDITORIUM

14.30-15.00. **MiniSymposium**: Antisecretory Factor - a clinical innovation in Ménière’s disease? (with the non conditioning contribute of POA Pharmaceuticals, Sweden)

14.30-14.35: Antisecretory factor and medical foods - novel therapy concepts
J.G Bruhn, Sweden

14.35-14.45: Antisecretory factor-inducing therapy improves patient-reported functional levels in Ménieré's disease
S.C. Leong, T. H. Lesser, UK

R. Teggi, V. Marcelli, Italy

15.15-16.45. **MiniSymposium**: BPPV – can we manage all with repositioning maneuvers? (under the auspices of Vestibular Academy International)

15.15-15.25: Introduction
N. Ozgirgin, Turkey

15.25-15.40: Pathophysiology of BPPV. What happens to outlets in the SSC in long term if not repositioned
M. Kameswaran, India

15.40-15.55: Is there any place of Medical treatment in BPPV. How much vitamin D levels affect?
F. Alpin Guneri, Turkey

15.55-16.10: Posterior canal involvement. Why does it occur so often. How is it diagnosed and treated
M. Mandalá, Italy

16.10-16.25: Lateral SSC apogeotropic nystagmus. What is the difficulty in it? Why do new manoeuvres come out. What is the best treatment
D. Nuti, Italy

16.25-16.40: Are the canalith repositioning manoeuvres effectively treat BPPV once? What to do following the manoeuvre? Are there any precautions to be instructed the patient? When should we consider for surgery.
V. Darrouzet, France

17.00: Opening ceremony

17.45-18.30: Opening Lecture: Meniere's Disease (Etiology, Pathogenesis, Pathology and Symptoms)
M.M. Paparella, USA

SUNDAY OCTOBER 18, 2015

AUDITORIUM

08.00-08.10: Introductory Message
M. Barbara, Italy

08.10-08.25: **Keynote Lecture 1**
The history of Ménieré's Symposium
D. Lim (USA)

08.30-09.30: **Human Pathological Findings**
08.30-08.43: The Histopathology of Meniere's Disease: Observations from the
Temporal Bone Collection at the Massachusetts Eye and Ear Infirmary
M. McKenna, J.B. Nadol, USA)

08.45-08.58: Ultrastructure and Immunohistochemistry of the Human Inner Ear Relevant for Menières Disease
A. Schrott-Fischer, W. Liu, R. Glueckert, H. Rask-Andersen, Austria/Sweden

09.00-09.13. Bast's valve & Ménière's disease
A. Belal, Egypt

09.15-09.28. ES size in Meniere and non Meniere patients
FH Linthicum, DJ Lim, USA

09.30-09.50. Keynote Lecture 2
Cochlear proteomics of fluid and ion transport
AF Ryan, USA

10.00-10.13. Gentamicin Distribution in the Ear Following Local Applications
A.N. Salt, F.B. Kraus, E.B. King, S.K. Plontke, USA/Germany

10.15-10.28. Drug delivery via the oval window
S. O'Leary, E. King, J. Fallon, D. Brown, A. Salt, Australia/USA

10.30-11.00. COFFEE-BREAK

11.00-11.20. Keynote Lecture 3
Human Endolymphatic Duct System, Transepithelial Water Channels and Cochlear Ultrastructure
H. Rask-Andersen, Sweden

11.30-11.38. The fine structure of the blood- perilymph barrier under normal, experimental and pathological conditions. An overview
K. Jahnke, D. Arweiler-Harbeck, Germany

11.40-11.48. The blood perilymph barrier is vulnerable to systemic inflammation but is minimally affected by cochlear macrophages
K. Hirose, S-Z Lee, J. Hartsock, A. Salt, USA

11.50-13.30. The function of the endolymphatic sac

11.50-12.03: A new murine model for Ménière’s disease - vasopressin induced endolymphatic hydrops
M. Takumida, Y Katagiri, M. Anniko, Japan/Sweden

12.05-12.18: Ultrastructure and gene expression in the human endolymphatic sac – novel evidence of multiple functions
MN Møller, S Kirkeby, K Qvortrup, J Vikeså, FC Nielsen, P Caye-Thomasen, Denmark

12.20-12.33: Ion transport in the endolymphatic sac epithelial cells on the basis of experimental animal researches
N. Mori, T. Miyashita, Japan

12.35-12.48: Potassium secretion via apical multiple potassium channels in human endolymphatic sac epithelium
SH Kim, BG Kim, JY Kim, JS Jung, JY Choi, Korea

12.50-13.03: Host Cell Factor C-1 (HCFC-1) in human ES.
J. Vrabec, USA

13.05-13.18:
A. Ishiyama, USA
13.30-14.20. **SYMPOSIUM ON ELECTRICAL VESTIBULAR STIMULATION**  
(with the non conditioning support of Medel, Austria)

13.30-13.40 Pivotal experimental basis  
Dan Merfeld, USA

R. Gluckert, Austria

14.00-14.10 Epidemiological data and candidacy  
Bryan Ward, USA

14.15-14.25. Surgical approach/Patient data  
J. P. Guyot, Switzerland

14.30-14.50: **Keynote Lecture 4**  
Regenerative medicine for the inner ear  
J. Ito, Japan

**AUDITORIUM**

15.00-16.30: **Diagnostic workout - Audiological**

15.00-15.13: On the use of depletion tests  
R. Dauman, France

15.15-15.28: Sensitivity and Specificity of ECochG, VNG, VEMP, and Rotary Chair in the Diagnosis of Meniere’s disease  
J. Ferraro, USA

15.30-15.43: Endocochlear hydrops; hydrostatic pressure; otoacoustic emissions, electrocochleography; hair cell physiology  
P. Avan, Y. Pavier, T. Mom, F. Giraudet, France

15.45-15.58: Use of multifrequency admittancemetry associated to glycerol test to assess hydrops – Normative values in healthy subjects  
V. Franco-Vidal, D. Bonnard, J. Nodimar, V. Darrouzet, France

16.00-16.13: Electrocochleography and vestibular evoked myogenic potential in Meniere’s disease  
S. Dabiri, S. N. Yazdani, P. Abolhasani, B. Amirzagar, N. Rezazadeh, Iran

16.15-16.28: Retrospective evaluation of hydrops diagnostic on Menière’s Disease  
T. Lenarz, Germany

**SALA SAN FRANCESCO**

15.00-16.30: **Diagnostic workout - Vestibular**

15.00-15.13: Vestibular assessment in Meniere’s disease and Migraine  
Y. Bayazit, Turkey

15.15-15.28: Ocular and cervical vestibular-evoked myogenic potentials to air conducted sound and bone conducted vibration in Ménière’s Disease  
L. Manzari, AM Burgess, H. MacDougall, IS Curthoys, Italy, Australia

15.30-15.43: Instrumental Assessment in Menière’s Disease: Which Role for video Head Impulse Test?  
A.P. Casani, N. Cerchiai, E. Navari, Italy

15.45-15.58: Ocular (o-VEMP) and Cervical (c-VEMP) VEMPs in Patients with "Clinically Certain" Meniere's Disease  
S. McIlhinney, G. O'Beirne, J. Gourley, J. Hornibrook, New Zealand

16.00-16.13: A comparison of neurotological and psychometric test results in
Ménière’s disease and phobic postural vertigo
L. Nimroda, L. Kise, M. Nimroda, Latvia

16.30-17.00  COFFEE-BREAK

AUDITORIUM

17.00-18.30.  Diagnostic workout - Imaging

17.00-17.13: A reappraisal of Menière’s disease supported by variable latency of symptoms and MRI visualization of the endolymphatic hydrops
I. Pyykkö, J. Zou, T. Nakashima, T. Yoshida, S. Naganawa, Finland/Japan

17.15-17.28: Endolymphatic hydrops in patients with unilateral and bilateral Meniere’s Disease

17.30-17.43. Hydrops MRI-Impact on Meniere’s disease.
K. Orimoto, S. O’Leary, Australia

17.45-17.58. MR Imaging of Inner Ear Endo-perilynphatic Spaces at 3 Tesla after Intratympanic Contrast Agent Administration in Definite Meniere’s Disease
S. Salice, A. Tartaro, G. Filograna Pignatelli, A. Pacella, F. Cazzato, G. Neri, Italy)

18.00-18.13. MRI evaluation of endolymphatic hydrops and clinical applications for surgical management
M. Sone, T. Yoshida, T. Mukaida, M. Teranishi, T. Nakashima, S. Naganawa, Japan

18.15-18.28. MRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of Meniere’s Disease
J. Hornibrook, E. Flook, S. Greig, M. Babbage, T. Goh, M. Coates, R. Care, P. Bird New Zealand

18.30-19.30  Barany Symposium: From mouse models to classification of Mb Ménière

18.30-18.43: The regenerating inner ear
H. Rask-Andersen, Sweden

18.45-18.58: Experimental induced hydrops - in vivo studies in mice
M. Magnusson, Sweden

19.00-19.13: Intratympanic treatment
E. Mira, Italy

19.15-19.28: Classification of Mb Meniere, a progress report
A. Lopez-Escamez, Spain

SALA SAN FRANCESCO

18.30-19.30  Endolymphatic Hydrops

18.30-18.43: Meniere disease and endolymphatic hydrops
C.A. Oliveira, Brazil

18.45-18.58: Are there NO news about the cochlear hydrops?
O. Michel, A. Hess, J. Su, D. Labbé, W. Blocj, Belgium

19.00-19.13: Anterior membranous labyrinth hydrops
S. Ferrara, F. Martines, P. Ferrara, Italy

19.15-19.28: Oxidative Stress, Redox Homeostasis and Cellular Stress
A. Serra, S. Cocuzza, P. di Mauro, L. Maiolino, Italy
08.00-08.20. **Keynote Lecture 4**
Immune-mediated Meniere’s disease
JP Harris, USA

08.30-09.30. **Immune system and Ménière’s disease**

08.30-08.43: Local treatment of immune-mediated hearing loss by anti-TNF alpha drugs
P. Lefebvre, Belgium

08.45-08.53: Autoimmunity as a Candidate for the Etiopathogenesis of Meniere’s Disease: Detection of Autoimmune Reactions and Diagnostic Biomarker Candidate
J. Jung, JY Kim, HJ Lee, M. Gi, BG Kim, JY Choi, SH Kim, Korea

08.55-09.03: Experience of immunological aspects of Ménière’s disease
A. Nacci, J. Matteucci, B. Fattori, S.O. Romeo, S. Berrettini, Italy

09.05-09.13: Neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio in patients with acute Meniere’s Disease
V. Squeo, D’Ambruoso PT, N. Quaranta, Italy

09.15-09.23. A locus in chromosome 6p21.33 associated with bilateral sensorineural hearing loss may define immunomediated variant in Meniere’s disease
JA Lopez Escamez, S. Cabrera, T. Requena, C. Martin-Sierra, L. Frejo, A. Batuecas, J. M. Espinosa-Sanchez, Spain

**SALA SAN FRANCESCO**

08.30-09.30. **Intratympanic Dexamethasone as a Treatment for Ménière’s Disease.**
(with the non conditioning contribute of Otonomy, USA)

08.30-08.40: Intratympanic Dexamethasone as a Treatment for Ménière’s Disease
J. Phillips, UK

08.40-09.00: Perilymph pharmacokinetics of glucocorticosteroids after intratympanic, intracochlear, and intralabyrinthine delivery
S. Plontke, A. Salt, Germany, USA

09.00-09.20: Results from a Phase 2b Clinical Trial to Assess the Safety and Efficacy of Extended-Release Dexamethasone Thermosensitive Gel for Intratympanic Administration in Subjects with Ménière’s Disease
P. Lambert, C. LeBel, USA

09.30-09.50. **Keynote Lecture 5**
Cerebral venous insufficiency in Ménière’s disease
R. Filipo, Italy

10.00-10.08. Chronic cerebro-spinal venous insufficiency in Meniere’s Disease: Diagnosis and Endovascular Treatment after 24-month follow up
G. Attanasio, A. Bruno, L. Califano, F. Ciciariello, M. Viccaro, E. Covelli, E. Masci, L. Cagnoni, D. Mastrangelo, F. Salafia, V. Giugliano, B. Bernardo, Italy

10.10-10.18: Idiopathic sudden sensorineural hearing loss and Ménière’s syndrome: the role of cerebral venous drainage
N. Quaranta, V. De Ceglie, M. Damiani, M.M. Ciccone, Italy
10.20-10.28. Endovascular Treatment of Vertigo Caused by Jugular Bulb Abnormalities
M. Hitier, LM Roussel, M. Humbert, S. Moreau, P. Courtheoux, V. Patron, France

SALA SAN FRANCESCO
10.00-10.30 MIGRAINE
10.00-10.08. Vertiginous migraine and Ménière's disease
CA Oliveira, RL Bezerra, C. Messias, F. Bahmad jr., Brazil
10.10-10.18. Vestibular Migraine in an Otolaryngology Clinic: Prevalence, Associated Symptoms, and Prophylactic Medication Effectiveness
A. Van Ombergen, V. van Rompey, P. Van de Heyning, F. I. Wuyts, Belgium
10.20-10.28. The many faces of migraine – auditory and vestibular presentation: a case study
B. Ceramic, P. Radomskij, UK

10.30-11.00. COFFEE-BREAK
11.00-12.30. Japanase Society of Equilibrium Research (JSER) Symposium
11.00-11.15. Introduction
M. Suzuki
11.15-11.30. Epidemiological characteristics of Meniere's disease in Japan
H. Shojaku, Y. Watanabe, H. Takakura, M. Tsubota
11.30-11.45. Diagnosis 1: Diagnostic standard for Meniere's disease based on the clinical guideline of the disease in Japan
Y. Watanabe
11.45-12.00. Diagnosis 2: Diagnosis of endolymphatic hydrops using 3T MRI in patients with Meniere's disease
S. Usami, H. Yoshimura, H. Fukuoka, K. Tsukada
12.00-12.15. Overview of the treatment of Meniere's disease in Japan
I. Koizuka
12.15-12.30. Discussion

SALA SAN FRANCESCO
11.00-12.30. SUDDEN HEARING LOSS & PERILYMPHATIC FISTULA & OTOTOXICITY
11.00-11.08. Otoacoustic emissions in sudden sensorineural hearing loss
A. Shupak, R. Zeidan, R. Shemesh, Israel
11.10-11.18. Long term transtympanic steroid treatment results in patients with acute cochlear hearing loss
M. Durmusoglu, Y. Olgun, E. Dogan, MA Kozen, EA Guneri, Turkey
11.20-11.28. Intratympanic Steroid Treatment for Acute Low Frequency Sensorineural Hearing Loss with Vertigo H. Shin, Korea
11.30-11.38. Effect of the hearing level of nonaffected ear and severity of acute hearing loss in patient with unilateral sudden deafness from the perspective of tinnitus L. Cvorovic, Serbia
11.40-11.48 MRI findings and compliance to perform MRI in patients with SSNHL
R. Khniefes, N. Yehudai, S. Masud, M. Luntz, Israel
11.50-11.58. Etiologies of central origin in SSNHL patients
Y-S Park, Korea
12.00-12.08. Intratympanic dexamethasome: potential in the prevention of cisplatin ototoxicity
A. Shupak, T. Marshak, L. Levi, M. Steiner, Israel

12.10-12.18. The Spontaneous Perilymph Fistula Conundrum- Do We Finally Have An Answer?
A. K. Gadre, I. Edwards, C. Rutledge-Roof, USA

12.20-12.28. Chronic disequilibrium as main symptom of bilateral perilymph fistula - case presentation
N. Arsovic, D. Pavlovic, Serbia

(with the non conditioning support of Mylan, Germany)

12.30-12.40: Epidemiology, statistics and research design
R. Shoehuber, Italy

12.40-12.50: MD patients in the acute stage
A. Casani, Italy

12.50-13.00: MD patients in the intercritic stage
N. Ozgirgin, Turkey

13.00-13.10: MD patients under rehabilitation
M. Lacour, France

13.10-13.25: Discussion

13.30-14.40. IT GENTAMYCIN TREATMENT IN MD

13.30-13.38: Gentamicin therapy in Menière's disease
P. Vannucchi, R. Pecci, R. Santimone, A. Mengucci, F. Di Giustino, Italy

G. Russo, R. Grassia, F. Mosca, C. A. Leone, Italy

13.50-13.58: Long term vestibular function evolution after gentamycin intra tympanic injection (MJ Esteve Fraysse, S. Nicolas, A. Weckel, B. Lepage, M Marx, B Fraysse, France

14.00-14.08: Monitoring of chemical labyrinthectomy by gentamicin injection assessed by video head impulse test and VEMPs in patients suffering from Meniere disease resistant to medical therapies.
Catherine de Waele, E. Chiarovano, G. Lamas, C. Magnani, H. MacDougall, I. Curthoys, France/Australia

14.10-14.18: Intratympanic Gentamicin for Meniere's Disease: Short- and Long-term Follow-up of Two Regimens of Treatment
A.P. Casani, N. Cerchial, E. Navari, Italy

14.20-14.28: Hearing loss following intratympanic gentamicin
D. Kaplan, Israel

14.30-14.38: Intratympanic gentamicin/dexametasome versus gentamicin alone in Ménie'res disease
D. Nuti, M. Mandalà, Italy
BPPV


14.00-14.08: Impact of cupulolithiasis on patients' well being A. Abid, R. Yousef, Tatjana Tomanovic, Sweden


AUDITORIUM

14.50-16.15 IT STEROID TREATMENT IN MD


15.00-15.08. Glucocorticoids stimulate endolymphatic water reabsorption in inner ear J. Nevoux, S. Viengchareun, I. Lema, AL Lecoq, M. Lombes, F. Ferrary, France


15.20-15.28. Effect of intratympanic dexamethasone on controlling tinnitus and hearing loss in Ménière's disease F. Memari, F. Hassannia, Iran

15.30-15.38. Intra-tympanic dexamethasone in the treatment of disabling vertigo in Meniere Disease J.J. Wazen, USA


15.50-15.58. Evaluation of long term effect of intratympanic dexamethoson therapy (ITD) in Menière’s Disease (MD) C. Candreia, A. Lehner, M. Gartner, T. Linder, Switzerland
16.00-16.10. Comparison of Intra-Tympanic Steroid Therapy Protocols for Meniere's disease between Centers in Three Mediterranean Countries
R. Perez, S. Battelino, A. Incesulu, Israel/Slovenia/Turkey

SALA SAN FRANCESCO

14.30-16.00  CLINICAL ISSUES

14.30-14.38. Relationship between hearing threshold at the affected and unaffected ear in unilateral Ménière's disease
R. Albera, A. Canal, C Cassandro, A. Albera, A. Sammartano, V. Boggio, M. Cerutti, F. Dagna, Italy
14.40-14.48. Historical insights about Proper Menière
O. Michel, Belgium
R. Albera, I Bin, C. Cassandro, A. Albera, A. Canale, J. Colombini, FC Gervasio, Italy
15.00-15.08. Gluten sensitivity and Ménière's disease
F. Di Berardino, D. Soi, D. Alpini, E. Filipponi, A. Cesarani, Italy
15.10-15.18. Otitis media and Ménière's disease
D. Djeric, Serbia
15.20-15.28. Meniere's disease and benign increased intracranial tension
B. Eldin Mostafa, Egypt
15.30-15.38. The social impact of Ménière's disease: the role of different treatment strategies
D. Nuti, M. Mandalá, Italy
A. Pirodda, C. Brandolini, C. Borghi, Italy
15.50-15.58. Manifestation of Lermoyez's syndrome in Meniere's disease patient
S. Kordis, Slovenia
16.00-16.08. Prevalence and features of inferior vestibular neuritis
R. Glatre, R. Kania, B. Verillaud, C. Domange, P. Herman, C. Hautefort, France

16.15-16.45. COFFEE-BREAK

16.45-17.15. AUDITORIUM/SALA SAN FRANCESCO

POSTER SESSION

AUDITORIUM

17.30-18.40. VESTIBULAR REHABILITATION

17.30-17.43. Principles of long-term vestibular rehabilitation
M. Lacour, France
17.45-17.53. Role of perineuronal nets in vestibular compensation
F. Dagna, A. Albera, D. Carulli, A. Faralli, F. Rossi, P. Giordano, R. Albera, Italy
17.55-18.03. Vestibular rehabilitation in Menière’s Disease  
R. Pecci, P. Vannucchi, R. Santimone, A. Mengucci, F. Di Giustino, B. Giammarco, Italy

18.05-18.13. Development of vestibular rehabilitation platform using immersive virtual reality system  
S.K. Hong, CG Song, HJ Jeon, Korea

AUDITORIUM

17.30-18.40. CANAL DEHISCENCE

17.30-17.43. Otic Capsule Dehiscence Syndrome: Longitudinal Cognitive and Neurobehavioral Functional Outcomes Before and After Repair  
P. Ashley Wackym, Carey D. Balaban, Heather T. Mackay, USA

17.45-17.53. Techniques of surgical repair  
T. Somers, Belgium

17.55-18.03. Semicircular canal malformations: clinical and instrumental findings  
C. Brandolini, A. Castellucci, G. Piras, A. Pirodda, Italy

18.05-18.13. Ocular vestibular evoked myogenic potentials to high frequencies show semicircular canal dehiscence  
L. Manzari, AM Burgess, H. MacDougall, IS Curthoys, Italy/Australia

18.15-18.23. Hearing outcome after transmastoid semicircular canal plugging  
V. Van Rompaey, G. Van Haesendonck, P. Van de Heyning, Belgium

TUESDAY OCTOBER 20, 2015

AUDITORIUM

08.00-09.00 MEDICAL/ALTERNATIVE TREATMENT IN MD

08.00-08.13 eHealth in Meniere’s disorder improves quality of life when medical therapy is not enough  
I. Pyykkö, Hi. Levo, J. Rasku, V. Manchaiah, E. Kentala, Finland/USA

08.15-08.23. Alternative medicine and non-invasive therapies for the treatment of Ménière's disease  
Maria Lauriello, Ilaria Salvi, Luisa Crosta, Marco Fusetti, Italy

08.25-08.33. Reduction of vertigo symptomatology with chronic use of weak asymmetric base-in prism spectacles (WABIPS) in Vestibular Migraine patients  
E. Vente, D. Zambrano, Alphen a/d Rijn/Lekkerkerk, Netherlands

08.35-08.43. Cervical Specific Protocol and Results for 300 Meniere's Disease Patients Followed for a Minimum of Five Years (Michael T. Burcon, USA)

08.45-08.53. Comparative evaluation of the effect of the Meniett™ device in patients with Menière’s disease  
D. Bernardeschi, E. Ferrary, D. Bouccara, O. Sterkers, France
08.00-09.00  SURGICAL OPTIONS IN MD

08.00-08.13.  Vestibular neurectomy for intractable MD  
    P. Tran Ba Huy, France
08.15-08.23.  Vestibular nerve sectioning in Ménière's disease  
    Y. Bayazit, Turkey
08.25-08.33.  The long-term reduction of vertigo and subjective dizziness by  
    tenotomy of the stapedius and tensor tympani muscles in definite  
    Meniere's disease  
    Benjamin Loader, Austria
08.35-08.43.  Otoneurological assessment in long-term follow-up after vestibular  
    neurectomy for Meniere's disease  
    F. Dagna, A. Albera, D. Carulli, A. Faralli, F. Rossi, P. Giordano, R.  
    Albera, Italy
08.45-08.53.  Comparing long-term outcomes: pressure treatment vs vestibular  
    neurectomy  
    E. Covelli, L. Volpini, S. Monini, M. Barbara, Italy

AUDITORIUM

09.00-10.30.  SAC SURGERY

09.00-09.08.  Ménière’s disease; Still indications for sac surgery ?  
    Per Moller, Norway
09.10-09.18.  Endolymphatic Sac surgery- Why we need it…  
    V. Darrouzet, France
09.20-09.28.  Sac surgery for treatment of Meniere Disease  
    R.F. Bento, Brazil
09.30-09.38.  Osteoplastic refinement in ES surgery  
    RA Bly, LG Duckert, USA
09.40-09.48.  Some Endolymphatic Sac (ELS) Surgeries had improved hearing  
    (AA) 72 CLASS A), NOT just stabilization(Class B). Why NOT  
    more Class A Results ...the Gold Standard should be universal for  
    all therapies?  
    I.K. Arenberg, USA
09.50-09.58.  Endolymphatic Sac Revision Surgery  
    M.M. Paparella, USA
10.00-10.08.  Endolymphatic sac surgery for patients with Ménière's disease  
    - long-term results after primary and revision surgery  
    Stefan Volkenstein, T. Sandberg, JP Thomas, S. Dazert, Germany
10.10-10.18.  Endolymphatic duct blockage: a new era in the treatment of  
    Ménière disease  
    I. Saliba, N. Gabri, M-H Asmar, D. Berbiche, Canada
VESTIBULAR DISORDERS

09.00-09.13. Meniere's Disease: what can we learn from vestibular implants  
J.T. Rubinstein, J.O. Phillips, L. Ling, K. Nie, USA

09.15-09.23. Subjective visual vertical and horizontal in the Indian Population  
G.A. Amit, K. Tyagi, A.M. Augustine, A. Lepcha, A. Bairaj, India

09.25-09.33. Improving diagnostics in patients with vestibular paroxysmia to treat them in an earlier phase of illness  
B. Ihtijarevic, V. Van Rompaey, P. van den Heyning, F. Wuyts, Belgium

09.35-09.43. Isolated and combined semicircular canal dysfunction in patients with unilateral vestibular schwannoma  
A.J. Beynon, Netherlands

09.45-09.53. Subjective Visual Vertical in Bilateral Vestibular Loss Role of Proprioception  
M. Toupet, C. Van Nechel, U. Duquesne, C. Hautefort, S. Heuschen, Alexis Bozorg Grayeli, France

10.30-10.30. COFFEE-BREAK

AUDITORIUM

11.00-11.20. Keynote Lecture 6  
Personalized medicine in cochlear implantation  
Hans-Peter Zenner, Germany

11.30-12.30. HEARING REHABILITATION IN MÉNIÈRE’S DISEASE

11.30-11.38. Hearing Rehabilitation with Cochlear Implants and Hearing Aids in Patients with Meniere’s disease  
M. Luntz, N. Yehudai, T. Shpak, Israel

11.40-11.48. Cochlear implantation in patients with unilateral hearing loss and Ménière’s Disease  
A. Ramos, Spain

11.50-11.58. Cochlear Implants in Meniere's Disease  
T. Lenarz, Germany

12.00-12.08. Cochlear Implantation in Meniere's disease: Is it worth the effort?  
M. Kameswaran, India

12.10-12.18. Cochlear implantation in Ménieres Disease  
G. M. Sprinzl, A. Wolf-Magele, J. Schnabl, Austria

12.20-12.28. Cochlear implant in asymetric menieric hearing loss  
Domenico Cuda, Alessandra Murri, Italy
11.30-12.30.  **EFFECT OF CI ON MENIERE DISEASE**

11.30-11.38. Strategy for end-stage Ménière's disease: labyrinthectomy with CI  
B. Gantz, M.R. Hansen, C. Dunn, R. Tyler, USA

P. Canzi, M. Manfrin, M. Perotti, F. Aprile, S. Quaglieri, G. Locatelli, D. Fresa D, M. Benazzo, Italy

11.50-11.58. Rehabilitation of fluctuating hearing loss by cochlear implant  
D. Bernardeschi, I. Mosnier, D. Bouccara, E. Ferrary, O. Sterkers, France

12.00-12.08. Cochlear Implantation as therapy option in single-sided deafness and vertigo caused by M. Menière  
R. Laszig, Germany

12.10-12.18. Spatial hearing improvement and long-term suppressive effect on tinnitus after cochlear implantation in single-sided-deaf patients with and without Ménière's disease  
V. van Rompaey, G. Mertens, P. Van de Heyning, Belgium

D. Zanetti, F. Di Berardino, E. Filipponi, L.O. Redaelli De Zinis, T. Sorrentino, S. Costanzo, A. Cesarani, Italy

12.30.  **Closure**